Posttransplant lymphoproliferative disease following liver transplantation
Authors:
- 1 June 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 16 (3) , 274-280
Abstract
Purpose of review Despite contemporary immunosuppressive regimens, posttransplant lymphoproliferative disease (PTLD) remains a major complication after liver transplantation. This review highlights advances in the understanding of the pathophysiology, diagnosis, and management of PTLD in liver transplant recipients. Recent findings The spectrum of PTLD after liver transplant ranges from polymorphic lymphoproliferation to high-grade monoclonal lymphoma and is usually related to outgrowth of lymphocytes infected with Epstein–Barr virus (EBV). Risk factors for PTLD include EBV-seronegativity of the recipient, young age, intensity of immunosuppression, and the first year posttransplant. Measurement of EBV load by quantitative polymerase chain reaction assays is an important aid in the surveillance and diagnosis of PTLD although the specificity for PTLD is only about 50% (specificity for EBV is ∼100%). In patients diagnosed with PTLD, management options include reduction of immunosuppression, rituximab, combination chemotherapy, and adoptive immunotherapy. Outcomes have improved because rituximab has been incorporated into treatment regimens, and immunotherapy approaches show promise. Summary PTLD is a significant complication after liver transplantation, particularly in children. Advances in early detection approaches have aided in the diagnosis and management of PTLD, but further research to identify better predictive biomarkers is needed to improve risk-based treatment strategies.Keywords
This publication has 65 references indexed in Scilit:
- Lymphomas differ in their dependence on Epstein-Barr virusBlood, 2011
- Immunologic and Virologic Analyses in Pediatric Liver Transplant Recipients with Chronic High Epstein‐Barr Virus LoadsThe Journal of Infectious Diseases, 2010
- Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphomaBritish Journal of Haematology, 2010
- Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative DisorderClinical Microbiology Reviews, 2010
- Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern EraJournal of Clinical Oncology, 2010
- How I treat EBV lymphoproliferationBlood, 2009
- Genetic and phenotypic analysis of B‐cell post‐transplant lymphoproliferative disorders provides insights into disease biologyHematological Oncology, 2008
- Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)Blood, 2006
- Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationCancer, 2005
- TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH THE ANTI-CD20 MONOCLONAL ANTIBODY RITUXIMAB ALONE IN AN ADULT AFTER LIVER TRANSPLANTATIONTransplantation, 2000